PROTAC LRRK2 Degrader Molecules as Potential Disease Modifying Therapeutics for Neurodegenerative Diseases
Time: 8:30 am
day: Conference Day One
Details:
- Overview of Arvinas’ PROTAC strategy for neurodegenerative diseases
- Review of in vitro and in vivo data for potent, orally bioavailable PROTAC LRRK2 degrader molecules
- Biomarker changes in non-human primates consistent with LRRK2 PROTAC mechanism of action
